Dravet Syndrome Clinical Trial
Official title:
An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
This is an open label study to evaluate the safety of ZX008 (fenfluramine) in patients with Dravet syndrome (DS) or Lennox Gastaut syndrome (LGS) who are being administered cannabidiol (CBD).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05651204 -
GABA Biomarkers in Dravet Syndrome
|
||
| Withdrawn |
NCT02910297 -
The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy
|
||
| Recruiting |
NCT04462770 -
EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome
|
Phase 2 | |
| Completed |
NCT02896608 -
Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome
|
||
| Withdrawn |
NCT05140122 -
LEONIDaS Caregivers Study
|
||
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT02091206 -
A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
|
Phase 2 | |
| Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
| Recruiting |
NCT05472389 -
Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome
|
N/A | |
| Active, not recruiting |
NCT05626634 -
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
|
Phase 2 | |
| Recruiting |
NCT01858285 -
Genetics of Epilepsy and Related Disorders
|
||
| Recruiting |
NCT04614506 -
Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome
|
||
| Recruiting |
NCT06118255 -
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
|
Phase 3 | |
| Recruiting |
NCT04611438 -
Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome
|
Phase 3 | |
| Completed |
NCT02091375 -
Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
|
Phase 3 | |
| Completed |
NCT05364021 -
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06112275 -
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03254680 -
Turmeric as Treatment in Epilepsy
|
N/A | |
| Terminated |
NCT02187809 -
Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
|
Phase 3 | |
| Withdrawn |
NCT02174094 -
Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
|
Phase 3 |